Peptide Analogues of Parathyroid Hormone and PTH-related Protein (BIDMC 694)

Category:    Therapeutics - Drugs

KeyWords:  Metabolic Diseases;  

BIDMC ID:    694

Abstract:

Invention Dr. Michael Rosenblatt and Dr. Michael Chorev have discovered a series of PTH and PTH-related polypeptide analogues which are PTH agonists and potentially useful for the treatment of patients with bone loss. In particular, the analogues include one or more amino acid substitutions at various positions. The substitutions utilize non-natural amino acids such as b3 and b2 amino acids which are b-substituted b-amino acid residues and a-substituted b-amino acid residues respectively. More details on these analogues are provided in the published PCT application (WO03/105772). Beth Israel Deaconess Medical Center is seeking a corporate partner for collaborative research and development of this project with the goal of producing an approved and commercialized therapeutic drug for the treatment of osteoporosis. Background Osteoporosis is the most common form of metabolic bone disease and is considered by the World Health Organization to be second only to cardiovascular diseases as a leading healthcare problem. Twenty-eight million Americans have or are at risk for osteoporosis, and by the year 2015, that number is expected to rise to 41 million. Current classes of drugs on the market include ones that act as Hormone Replacement Therapy (e.g., Premarin®) and Selective Estrogen Receptor Modulators (e.g., Evista®), and Bisphosphonates (e.g., Fosamax®). A new class of therapies includes the anabolic therapies of PTH such as Forteo and the analogues developed by Drs. Rosenblatt and Chorev as described above. These PTH-like therapeutic compounds are designed to build bone mass in contrast to currently available therapeutics that are designed to inhibit bone resorption.

Inventor:   Drs. Rosenblatt and Chorev are world renowned researchers in the area of osteoporosis and PTH. In particular, their academic work while at BIDMC and Harvard Medical School and funded by the NIH focused on parathyroid hormone-receptor interactions.

Commercial Opportunity:

Osteoporosis is the most common form of metabolic bone disease and is considered by the World Health Organization to be second only to cardiovascular diseases as a leading healthcare problem. Twenty-eight million Americans have or are at risk for osteoporosis, and by the year 2015, that number is expected to rise to 41 million.

Competitive Advantages:

These PTH-like therapeutic compounds are designed to build bone mass in contrast to currently available therapeutics that are designed to inhibit bone resorption.

Related Publications:

State of Development:

Beth Israel Deaconess Medical Center is seeking a corporate partner for collaborative research and development of this project with the goal of producing an approved and commercialized therapeutic drug for the treatment of osteoporosis.

Related Technology URL:

http://research.bidmc.harvard.edu/research/ResearchPIInfo.ASP?Submit=Display&PersonID=122

Patent Status:

PCT foreign application designating all countries is currently pending

TVO Contact Info:
     Stanley C Mah
     Senior Associate TVO
     smah@bidmc.harvard.edu
     Phone: 617-667-0573   Fax: 617-667-0646

     Beth Israel Deaconess Medical Center
     Technology Ventures Office  Room: BR-0200
     330 Brookline Avenue
     Boston, MA 02215